Should Investors Buy or Sell Inovio Pharmaceuticals Right Now?

Should Investors Buy or Sell Inovio Pharmaceuticals Right Now?

Before joining The Motley Fool, Mark worked as a freelance financial writer covering a variety of markets.. As COVID-19 outbreaks continue to spread around the world, biotech stocks working on possible treatments have become all the rage.. Inovio Pharmaceuticals ( NASDAQ:INO ) has been one of the hottest biotech stocks on the market, with shares continuing to see dramatic price swings in both directions as the COVID-19 pandemic continues to spread.. VGX-3100 is undergoing one phase 3 and two phase 2 trials, with results expected this year. Its main rival in the COVID-19 vaccine market is Moderna ( NASDAQ:MRNA ) , which is developing an mRNA-based vaccine for the virus.. Moderna's treatment is still experimental, with this COVID-19 vaccine being the first time that the company has tried to treat a virus of this type.. Inovio already has experience in developing a vaccine against a very similar virus, MERS.. Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return.